PRMT inhibition ameliorates symptoms associated with spinal muscular atrophy (SMA) by targeting neuroinflammation, suggesting its potential as a standalone or adjunctive treatment.20 The imbalance between PRMT1 and DDAH (dimethylarginine dimethylaminohydrolase) is associated with hyperglycemia-induced endothelial dysfunction. Here, PRMT1 is linked to spinal muscular atrophy.